Iridex Announces Publication Of 2-Yr Clinical Study Demonstrating Favorable Outcomes With TLT Using MicroPulse Technology In Patients With Primary Glaucoma

Iridex Corporation (NASDAQ: IRIX) has announced the publication of a two-year clinical study showing favorable outcomes for transscleral laser therapy (TLT) using its MicroPulse Technology in patients with varying stages of primary glaucoma. This development highlights Iridex's position as a leader in innovative laser-based medical systems for treating glaucoma.